Drug intelligence / Profile preview

EVG-311

Development stage: Preclinical
Lead developer: Lantheus
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

EVG-311 is a molecularly targeted tracer developed for the treatment and diagnosis of glioblastoma (GBM) and other glial tumors. It binds to a specific glial cell surface molecule, enabling targeted imaging or therapy of malignant glial cells. Glioblastoma remains one of the most challenging cancers in oncology, with a very low five-year survival rate. The agent is being developed as both a diagnostic and potentially therapeutic radiotracer, with at least one form labeled as 68Ga-EVG-311 for imaging purposes[1][2][3].

Other names: 68Ga-EVG-311

Beyond the preview

Go deeper on EVG-311.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVG-311.

Explore the full profile